biostudies-literatureUnknown22(1)Papalexi ELundbeck Hellas<h4>Background</h4>Functional recovery is an important treatment goal in major depressive disorder (MDD). This study assessed the real-world effectiveness of vortioxetine in patients with MDD, with particular focus on functioning; dose-response was also assessed.<h4>Methods</h4>This was a non-interventional, prospective, multicenter study conducted in Greece. Adult outpatients with MDD (n = 336) initiating vortioxetine (5-20 mg/day flexible dosing) as treatment for a current major depressive episode were followed for 3 months. Analyses were stratified according to vortioxetine dosage at 3 months: 5-10 mg/day versus 15-20 mg/day. Functioning was assessed using the Sheehan Disability Scale (SDS).<h4>Results</h4>Mean ± standard error SDS total score decreased (improved) from 18.7 ± 0.3 at basBMC psychiatry548https://www.ebi.ac.uk/biostudies/studies/S-EPMC9373318biostudies-literatureReal-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects.PMC9373318Panagiotidis PPapalexi EKaravelas EMarkopoulou MBalta GGalanopoulos AEttrup AKontis DVlachos TfalseReal-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects.<h4>Background</h4>Functional recovery is an important treatment goal in major depressive disorder (MDD). This study assessed the real-world effectiveness of vortioxetine in patients with MDD, with particular focus on functioning; dose-response was also assessed.<h4>Methods</h4>This was a non-interventional, prospective, multicenter study conducted in Greece. Adult outpatients with MDD (n = 336) initiating vortioxetine (5-20 mg/day flexible dosing) as treatment for a current major depressive episode were followed for 3 months. Analyses were stratified according to vortioxetine dosage at 3 months: 5-10 mg/day versus 15-20 mg/day. Functioning was assessed using the Sheehan Disability Scale (SDS).<h4>Results</h4>Mean ± standard error SDS total score decreased (improved) from 18.7 ± 0.3 at bas2022-01-01T00:00:00Z2022 Aug2025-04-19T18:56:49.223Z2025-04-19T18:56:49.223ZS-EPMC93733183596236910.1186/s12888-022-04109-5